The latest findings presented at the 2024 San Antonio Breast Cancer Symposium (SABCS) reveal that patients with germline BRCA ...

AbbVie has announced plans to acquire Nimble Therapeutics in a $200 million deal. The acquisition brings Nimble’s pioneering ...

Imlunestrant, an oral SERD, significantly prolonged progression-free survival in patients with advanced ER+, HER2- breast ...

Nektar Therapeutics announced promising results from a Phase 2 study of its experimental drug NKTR-255, which improved ...

Merck has announced that the Phase 3 KEYLYNK-001 trial demonstrated that KEYTRUDA® (pembrolizumab) combined with chemotherapy ...

General Inception, a global biotech company igniter, has acquired Enable Medicine, a leader in Artificial Intelligence-driven ...

The DREAMM-7 trial shows belantamab mafodotin combined with bortezomib and dexamethasone significantly improves overall ...

The AMPLIFY Phase III trial demonstrates that acalabrutinib plus venetoclax significantly improves progression-free survival ...

FDA has granted accelerated approval to Bizengri® (zenocutuzumab-zbco), a first-in-class bispecific antibody targeting NRG1+ ...

Roche has announced a definitive agreement to acquire Poseida Therapeutics, a clinical-stage biopharmaceutical company ...

Adding BLINCYTO® (blinatumomab) to chemotherapy significantly improves three-year disease-free survival (96%) in children ...

FDA has approved Durvalumab (Imfinzi) as the first and only immunotherapy for adult patients with limited-stage small cell ...